Featured Press Releases

FDA Accepts sBLA Filing of Leqembi® (lecanemab-irmb) for IV Maintenance Dosing in Early Alzheimer

FDA Accepts sBLA Filing of Leqembi® (lecanemab-irmb) for IV Maintenance Dosing in Early Alzheimer's Treatment

nuBioAge, nuHx, and Marius Pharmaceuticals launch a collaborative GLP-1 comparison study in male patients.

nuBioAge, nuHx, and Marius Pharmaceuticals launch a collaborative GLP-1 comparison study in male patients.

  • 25 Sep 2024

nuBioAge, a longevity science and wellness network based in West Palm Beach, has announced a...

Neurocrine Biosciences begins Phase 1 trial on NBI-1065890, a second-gen VMAT2 inhibitor, in healthy adults

Neurocrine Biosciences begins Phase 1 trial on NBI-1065890, a second-gen VMAT2 inhibitor, in healthy adults

Restore Hyper Wellness has partnered with MECOTEC to enhance their offerings in cryotherapy solutions.

Restore Hyper Wellness has partnered with MECOTEC to enhance their offerings in cryotherapy solutions.

Bruker complements fast and cost-effective IR Biotyper® hospital hygiene testing and HAI tracing with NGS reflex testing

Bruker complements fast and cost-effective IR Biotyper® hospital hygiene testing and HAI tracing with NGS reflex testing

Leqembi® has received approval for intravenous maintenance treatment in China

Leqembi® has received approval for intravenous maintenance treatment in China

FDA Approves New 2-Gram Fibryga® Presentation to Improve Convenience and Precision in Treating Acquired Fibrinogen Deficiency

FDA Approves New 2-Gram Fibryga® Presentation to Improve Convenience and Precision in Treating Acquired Fibrinogen Deficiency

  • Octapharma
  • 08 Jan 2026
Ark Biopharmaceutical Granted China Marketing Authorization for Aizhida in ADHD Treatment

Ark Biopharmaceutical Granted China Marketing Authorization for Aizhida in ADHD Treatment

  • Arkbio
  • 08 Jan 2026
Novotech Appoints Anand Tharmaratnam as Chief Executive Officer

Novotech Appoints Anand Tharmaratnam as Chief Executive Officer

  • Novotech
  • 08 Jan 2026
Coya Therapeutics Announces Results from an Investigator-Initiated Study Showing Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients Treated with Low-Dose IL-2 and CTLA4-Ig

Coya Therapeutics Announces Results from an Investigator-Initiated Study Showing Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients Treated with Low-Dose IL-2 and CTLA4-Ig

  • Coya Therapeutics, Inc.
  • 08 Jan 2026
RoslinCT and BOOST Pharma Form Strategic Manufacturing Partnership to Advance Cell Therapy for Osteogenesis Imperfecta

RoslinCT and BOOST Pharma Form Strategic Manufacturing Partnership to Advance Cell Therapy for Osteogenesis Imperfecta

  • RoslinCT and BOOST Pharma
  • 07 Jan 2026
Orum Therapeutics Names Chad May Chief Scientific Officer to Advance Degrader-Antibody Conjugate Programs

Orum Therapeutics Names Chad May Chief Scientific Officer to Advance Degrader-Antibody Conjugate Programs

  • Orum Therapeutics
  • 05 Jan 2026
Drug Discovery 2024
The Digital Pharma Advances Conference 2026

Most Popular
January   2026
M T W T F S S
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31  

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.